Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(4):387–398. doi: 10.1111/j.1527-3458.2001.tb00206.x

The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous System

Jie Zhu 1,✉, Eilhard Mix 2, Bengt Winblad 1
PMCID: PMC6741679  PMID: 11830756

ABSTRACT

Rolipram is a selective inhibitor of phosphodiesterases (PDE) IV, especially of the subtype PDE IVB. These phosphodiesterases are responsible for hydrolysis of the cyclic nucleotides cAMP and cGMP, particularly in nerve and immune cells. Consequences of rolipram‐induced elevation of intracellular cAMP are increased synthesis and release of norepinephrine, which enhance central noradrenergic transmission, and suppress expression of proinflammatory cytokines and other mediators of inflammation. In humans and animals rolipram produces thereby a variety of biological effects. These effects include attenuation of endogenous depression and inflammation in the central nervous system (CNS), both effects are of potential clinical relevance. There are some discrepancies between in vitro and in vivo effects of rolipram, as well as between results obtained in animal models and clinical studies. The clinical use of rolipram is limited because of its behavioral and other side effects. Newly developed selective PDE IV inhibitors with presumably higher potency and lower toxicity are currently under investigation.

Keywords: cAMP, Central nervous system (CNS), Phosphodiesterases, Rolipram

Full Text

The Full Text of this article is available as a PDF (168.9 KB).

References

  • 1. Abbas N, Zou LP, Pelidou SH, Winblad B, Zhu J. Protective effect of rolipram in experimental autoimmune neuritis: Protection is associated with down‐regulation of IFN‐gamma and inflammatory chemokines as well as up‐regulation of IL‐4 in peripheral nervous system. Autoimmunity 2000;32:93–99. [DOI] [PubMed] [Google Scholar]
  • 2. Agnello D, Carvelli L, Muzio V, et al. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: Relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol 2000;109:105–111. [DOI] [PubMed] [Google Scholar]
  • 3. Angel JB, Saget BM, Walsh SP, et al. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV‐1 replication. AIDS 1995;9:1137–1144. [DOI] [PubMed] [Google Scholar]
  • 4. Araki T, Kato H, Shuto K, Itoyama Y. Age‐related changes in [3H]nimodipine and [3H]rolipram binding in the rat brain. J Pharm Pharmacol 1997;49:310–314. [DOI] [PubMed] [Google Scholar]
  • 5. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high‐affinity rolipram binding site. J Pharmacol Exp Ther 1995;273:1396–1402. [PubMed] [Google Scholar]
  • 6. Bellamy TC, Garthwaite J. cAMP‐specific” phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide. Mol Pharmacol 2001;59:54–61. [DOI] [PubMed] [Google Scholar]
  • 7. Bertolino A, Crippa D, di Dio S, et al. Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: A double‐blind double‐dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 1988;3:245–253. [DOI] [PubMed] [Google Scholar]
  • 8. Beshay E, Croze F, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 2001;98:272–279. [DOI] [PubMed] [Google Scholar]
  • 9. Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase‐4 and‐3 inhibitors in Th1‐mediated autoimmune diseases. J Immunol 2000;164:1117–1124. [DOI] [PubMed] [Google Scholar]
  • 10. Block F, Bozdag I, Nolden‐Koch M. Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats. Neurosci Lett 2001;298:103–106. [DOI] [PubMed] [Google Scholar]
  • 11. Bobon D, Breulet M, Gerard‐Vandenhove MA, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double‐dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 1988;238:2–6. [DOI] [PubMed] [Google Scholar]
  • 12. Borisy FF, Hwang PN, Ronnett GV, Snyder SH. High‐affinity cAMP phosphodiesterase and adenosine localized in sensory organs. Brain Res 1993;610:199–207. [DOI] [PubMed] [Google Scholar]
  • 13. Briggs WA, Wu Q, Orgul O, Choi M, Scheel PJ Jr, Burdick J. Lymphocyte suppression by rolipram with other immunosuppressive drugs. J Clin Pharmacol 1999;39:794–799. [DOI] [PubMed] [Google Scholar]
  • 14. Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL‐12 signaling and IL‐12‐mediated Th1 differentiation: An effect of the novel anti‐inflammatory drug lisofylline. J Immunol 1998;161:7015–7022. [PubMed] [Google Scholar]
  • 15. Carpenter DO, Briggs DB, Knox AP, Strominger N. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophysiol 1988;59:358–369. [DOI] [PubMed] [Google Scholar]
  • 16. Chan SC, Li SH, Hanifin JM. Increased interleukin‐4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate‐phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993;100:681–684. [DOI] [PubMed] [Google Scholar]
  • 17. Chang YH, Conti M, Lee YC, Lai HL, Ching YH, Chern Y. Activation of phosphodiesterase IV during de‐ sensitization of the A2A adenosine receptor‐mediated cyclic AMP response in rat pheochromocytoma (PC12) cells. J Neurochem 1997;69:1300–1309. [DOI] [PubMed] [Google Scholar]
  • 18. Cherry JA, Thompson BE, Pho V. Diazepam and rolipram differentially inhibit cyclic AMP‐specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim Biophys Acta 2001;1518:27–35. [DOI] [PubMed] [Google Scholar]
  • 19. Constantinescu CS, Hilliard B, Lavi E, Ventura E, Venkatesh V, Rostami A. Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline. J Neurol Sci 1996;143:14–18. [DOI] [PubMed] [Google Scholar]
  • 20. Cowburn RF, Fowler CJ, O'Neill C. Neurotransmitters, signal transduction and second‐messengers in Alz heimer's disease. Acta Neurol Scand 1996;165 (Suppl): 25–32. [DOI] [PubMed] [Google Scholar]
  • 21. Engels P, Fichtel K, Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994;350:291–295. [DOI] [PubMed] [Google Scholar]
  • 22. Essayan DM, Huang SK, Undem BJ, Kagey‐Sobotka A, Lichtenstein LM. Modulation of antigen‐ and mitogen‐induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994;153:3408–3416. [PubMed] [Google Scholar]
  • 23. Essayan DM, Huang SK, Kagey‐Sobotka A, Lichtenstein LM. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen‐induced cytokine gene expression in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 1995;13:692–702. [DOI] [PubMed] [Google Scholar]
  • 24. Essayan DM, Kagey‐Sobotka A, Lichtenstein LM, Huang SK. Regulation of interleukin‐13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen‐specific human T lymphocyte clones. Biochem Pharmacol 1997;53:1055–1060. [DOI] [PubMed] [Google Scholar]
  • 25. Folcik VA, Smith T, O'Bryant S, et al. Treatment with BBB022A or rolipram stabilizes the blood‐brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J Neuroimmunol 1999;97:119–128. [DOI] [PubMed] [Google Scholar]
  • 26. Fujimaki K, Morinobu S, Duman RS. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant‐induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 2000;22:42–51. [DOI] [PubMed] [Google Scholar]
  • 27. Genain CP, Roberts T, Davis RL, et al. Prevention of autoimmune demyelination in non‐human primates by a cAMP‐specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995;92:3601–3605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Hamdy MM, Mamiya T, Noda Y, et al. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c‐Fos protein expression in morphine dependent mice. Behav Brain Res 2001;118:85–93. [DOI] [PubMed] [Google Scholar]
  • 29. Hatzelmann A, Schudt C. Anti‐inflammatory and immunomodulatory potential of the novel PDE IV inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267–279. [PubMed] [Google Scholar]
  • 30. Heaslip RJ, Evans DY. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 1995;286:281–290. [DOI] [PubMed] [Google Scholar]
  • 31. Hebenstreit GF, Fellerer K, Fichte K, et al. Rolipram in major depressive disorder: Results of a double‐blind comparative study with imipramine. Pharmacopsychiatry 1989;22:156–160. [DOI] [PubMed] [Google Scholar]
  • 32. Hoehn‐Saric R. Neurotransmitters in anxiety. Arch Gen Psychiatry 1982;39:735–742. [DOI] [PubMed] [Google Scholar]
  • 33. Hogan CJ, Fang GD, Scheld WM, Linden J, Diduch DR. Inhibiting the inflammatory response in joint sepsis. Arthroscopy 2001;17:311–315. [DOI] [PubMed] [Google Scholar]
  • 34. Howell LL. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 1993;266:894–903. [PubMed] [Google Scholar]
  • 35. Jimenez JL, Gonzalez‐Nicolas J, Alvarez S, Fresno M, Munoz‐Fernandez MA. Regulation of human immunodeficiency virus type 1 replication in human T lymphocytes by nitric oxide. J Virol 2001;75:4655–4663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Jung S, Zielasek J, Kollner G, Donhauser T, Toyka K, Hartung HP. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996;68:1–11. [DOI] [PubMed] [Google Scholar]
  • 37. Kehr W, Debus G, Neumeister R. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. J Neural Transm 1985;63:1–12. [DOI] [PubMed] [Google Scholar]
  • 38. Krause DS, Deutsch C. Cyclic AMP directly inhibits IL‐2 receptor expression in human T cells: Expression of both p55 and p75 subunits is affected. J Immunol 1991;146:2285–2296. [PubMed] [Google Scholar]
  • 39. Krause W, Kuhne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988;18:561–571. [DOI] [PubMed] [Google Scholar]
  • 40. Larson JL, Pino MV, Geiger LE, Simeone CR. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 1996;78:44–49. [DOI] [PubMed] [Google Scholar]
  • 41. MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP‐response‐element‐binding protein (CREB) and p38 mitogen‐activated protein (MAP) kinase in U937 monocytic cells. Biochem J 2000;347:571–578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Madelian V, La Vigne E. Rapid regulation of a cyclic AMP‐specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Biochem Pharmacol 1996;51:1739–1747. [DOI] [PubMed] [Google Scholar]
  • 43. Maghazachi AA. Tumor necrosis factor‐alpha is chemokinetic for lymphokine‐activated killer cells: Regulation by cyclic adenosine monophosphate. J Leukoc Biol 1991;49:302–308. [DOI] [PubMed] [Google Scholar]
  • 44. Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ, Barnette MS. Prolonged beta adrenoceptor stimulation up‐regulates cAMP phosphodiesterase activity in human. Exp Ther 1996;276:810–818. [PubMed] [Google Scholar]
  • 45. Martinez I, Puerta C, Redondo C, Garcia‐Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: Sequential gene expression analysis of cytokines, adhesion mole cules and the inducible nitric oxide synthase. J Neurol Sci 1999;164:13–23. [DOI] [PubMed] [Google Scholar]
  • 46. Mori T, Baba J, Ichimaru Y, Suzuki T. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Jpn J Pharmacol 2000;83:113–118. [DOI] [PubMed] [Google Scholar]
  • 47. Nam G, Yoon CM, Kim E, et al. Syntheses and evaluation of pyrido[2,3‐dlpyrimidine‐2,4‐diones] as PDE 4 inhibitors. Bioorg Med Chem Lett 2001;11:611–614. [DOI] [PubMed] [Google Scholar]
  • 48. Navikas V, Matusevicius D, Soderstrom M, Pirskanen R, Fredrikson S, Link H. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP‐reactive IFN‐gamma and TNF‐alpha mRNA ex pressing blood mononuclear cells in patients with multiple sclerosis. Clin Neuropharmacol 1998;21:236–244. [PubMed] [Google Scholar]
  • 49. Norman TR, Judd FK, Burrows GD. New pharmacological approaches to the management of depression: From theory to clinical practice. Aust NZ J Psychiatry 1992;26:73–81. [DOI] [PubMed] [Google Scholar]
  • 50. Novak TJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 1990;87:9353–9357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Overstreet DH, Double K, Schiller GD. Antidepressant effects of rolipram in a genetic animal model of de pression: Cholinergic supersensitivity and weight gain. Pharmacol Biochem Behav 1989;34:691–696. [DOI] [PubMed] [Google Scholar]
  • 52. Perez‐Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry. J Chem Neuroanat 2000;20:349–374. [DOI] [PubMed] [Google Scholar]
  • 53. Persidsky Y, Limoges J, Rasmussen J, Zheng J, Gearing A, Gendelman HE. Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV‐1 encephalitis. J Neuroimmunol 2001;114:57–68. [DOI] [PubMed] [Google Scholar]
  • 54. Prabhakar U, Lipshutz D, Bartus JO, et al. Characterization of cAMP‐dependent inhibition of LPS‐induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994;16:805–816. [DOI] [PubMed] [Google Scholar]
  • 55. Przegalinski E, Bigajska K, Lewandowska A. The influence of rolipram on the central serotoninergic system. Pharmacopsychiatria 1981;14:162–166. [DOI] [PubMed] [Google Scholar]
  • 56. Ramafi G, Anderson R, Theron AJ, et al. CGS 21680, dibutyryl cyclic AMP and rolipram attenuate the pro‐inflammatory interactions of the Pseudomonas aeruginosa‐derived pigment, 1‐hydroxyphenazine, with human neutrophils. Pulm Pharmacol Ther 2000;13:293–299. [DOI] [PubMed] [Google Scholar]
  • 57. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996;64:193–200. [DOI] [PubMed] [Google Scholar]
  • 58. Rieckmann P, Weber F, Gunther A, Poser S. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon‐beta 1b treatment in patients with multiple sclerosis. Neurology 1996;47:604. [DOI] [PubMed] [Google Scholar]
  • 59. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001;40:262–269. [DOI] [PubMed] [Google Scholar]
  • 60. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745–1751. [DOI] [PubMed] [Google Scholar]
  • 61. Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Bohmer F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry 1992;32:668–681. [DOI] [PubMed] [Google Scholar]
  • 62. Sasaki H, Hashimoto K, Maeda Y, et al. Rolipram, a selective c‐AMP phosphodiesterase inhibitor sup presses oro‐facial dyskinetic movements in rats. Life Sci 1995;56:443–447. [DOI] [PubMed] [Google Scholar]
  • 63. Schultz JE, Schmidt BH. Rolipram, a stereospecific inhibitor of calmodulin‐independent phosphodiesterase, causes beta‐adrenoceptor subsensitivity in rat cerebral cortex. Naunyn Schmiedeberg's Arch Pharmacol 1986;333:23–30. [DOI] [PubMed] [Google Scholar]
  • 64. Schwabe U, Miyake M, Ohga Y, Daly JW. 4‐(3‐Cyclopentyloxy‐4‐methoxyphenyl)‐2‐pyrrolidone (ZK 62711): A potent inhibitor of adenosine cyclic 3′,5′‐monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 1976;12:900–910. [PubMed] [Google Scholar]
  • 65. Scott AI, Perini AF, Shering PA, Whalley LJ. In‐patient major depression: Is rolipram as effective as amitriptyline Eur J Clin Pharmacol 1991;40:127–129. [DOI] [PubMed] [Google Scholar]
  • 66. Secchiero P, Zella D, Curreli S, et al. Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat‐mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci USA 2000;97:14620–14625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Shelton RC, Mainer DH, Sulser F. cAMP‐dependent protein kinase activity in major depression. Am J Psychiatry 1996;153:1037–1042. [DOI] [PubMed] [Google Scholar]
  • 68. Smith KJ, Skelton HG, Yeager J, Lee RB, Wagner KF. Pruritus in HIV‐1 disease: Therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997;195:353–358. [DOI] [PubMed] [Google Scholar]
  • 69. Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995;1:244–248. [DOI] [PubMed] [Google Scholar]
  • 70. Sommer N, Martin R, McFarland HF, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997;79:54–61. [DOI] [PubMed] [Google Scholar]
  • 71. Sturgess I, Searle GF. The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality. Br J Clin Pharmacol 1990;29:369–370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP‐dependent inhibition of human neutrophil oxidative activity by substituted 2‐propynylcyclohexyl adenosine A (2A) receptor agonists. Br J Pharmacol 2001;132:1017–1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Thompson WJ. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol Ther 1991;51:13–33. [DOI] [PubMed] [Google Scholar]
  • 74. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 1991;46:512–523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. van Oosten BW, Rep MH, van Lier RA, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996;66:49–55. [DOI] [PubMed] [Google Scholar]
  • 76. van Staveren WC, Markerink‐van Ittersum M, Steinbusch HW, de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 2001;888:275–286. [DOI] [PubMed] [Google Scholar]
  • 77. Wachtel H. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′‐monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl) 1982;77:309–316. [DOI] [PubMed] [Google Scholar]
  • 78. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′‐monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983;22:267–272. [DOI] [PubMed] [Google Scholar]
  • 79. Weishaar RE, Kobylarz‐Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP‐specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987;61:539–547. [DOI] [PubMed] [Google Scholar]
  • 80. Whalin ME, Garrett RL, Thompson WJ, Strada SJ. Correlation of cell‐free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices. Second Messengers Phosphoproteins 1988;12:311–325. [PubMed] [Google Scholar]
  • 81. Zeller E, Stief HJ, Pflug B, Sastre‐y‐Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984;17:188–190. [DOI] [PubMed] [Google Scholar]
  • 82. Zhao Y, Yu M, Chen M, Elder RT, Yamamoto A, Cao J. Pleiotropic effects of HIV‐1 protein R (Vpr) on morphogenesis and cell survival in fission yeast and antagonism by pentoxifylline. Virology 1998;246:266–276. [DOI] [PubMed] [Google Scholar]
  • 83. Zou LP, Deretzi G, Pelidou SH, et al. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 2000;39:324–333. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES